Drug Approval | October 04, 2024
Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
This is used to treat central diabetes insipidus and bedwetting
This is used to treat central diabetes insipidus and bedwetting
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Establishing Asymchem’s first manufacturing footprint in Europe
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Subscribe To Our Newsletter & Stay Updated
